Analysts Set Amarin Co. plc (NASDAQ:AMRN) Price Target at $28.40

Shares of Amarin Co. plc (NASDAQ:AMRN) have been given a consensus recommendation of “Buy” by the twelve brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $28.00.

Several brokerages recently issued reports on AMRN. HC Wainwright restated a “buy” rating on shares of Amarin in a report on Thursday, August 1st. BidaskClub lowered shares of Amarin from a “hold” rating to a “sell” rating in a report on Wednesday, July 24th. Leerink Swann began coverage on shares of Amarin in a report on Wednesday, August 14th. They issued an “outperform” rating on the stock. Svb Leerink began coverage on shares of Amarin in a report on Wednesday, August 14th. They issued an “outperform” rating and a $26.00 price objective on the stock. Finally, Stifel Nicolaus restated a “buy” rating and issued a $26.00 price objective on shares of Amarin in a report on Wednesday, July 31st.

AMRN traded up $0.51 on Wednesday, hitting $15.66. The company had a trading volume of 8,244,200 shares, compared to its average volume of 8,113,073. The firm has a market cap of $5.41 billion, a P/E ratio of -40.15 and a beta of 1.15. Amarin has a 1 year low of $2.65 and a 1 year high of $23.91. The company’s fifty day moving average price is $18.90 and its 200 day moving average price is $18.67. The company has a current ratio of 2.01, a quick ratio of 1.76 and a debt-to-equity ratio of 0.18.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.01. The firm had revenue of $100.40 million for the quarter, compared to analyst estimates of $99.54 million. Amarin had a negative net margin of 27.51% and a negative return on equity of 111.75%. Amarin’s revenue was up 90.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.10) EPS. On average, analysts predict that Amarin will post -0.2 earnings per share for the current year.

In other Amarin news, Director David M. Stack sold 51,991 shares of the business’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $22.28, for a total transaction of $1,158,359.48. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Aaron Berg sold 113,195 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $18.59, for a total transaction of $2,104,295.05. The disclosure for this sale can be found here. Insiders have sold 629,214 shares of company stock worth $12,804,139 over the last quarter. Insiders own 2.75% of the company’s stock.

Large investors have recently modified their holdings of the business. Chartwell Investment Partners LLC boosted its holdings in shares of Amarin by 4.6% in the second quarter. Chartwell Investment Partners LLC now owns 342,760 shares of the biopharmaceutical company’s stock valued at $6,646,000 after acquiring an additional 15,083 shares during the period. University of Notre Dame DU Lac boosted its holdings in shares of Amarin by 43.1% in the second quarter. University of Notre Dame DU Lac now owns 212,950 shares of the biopharmaceutical company’s stock valued at $4,129,000 after acquiring an additional 64,113 shares during the period. Verition Fund Management LLC boosted its holdings in shares of Amarin by 28.8% in the second quarter. Verition Fund Management LLC now owns 38,541 shares of the biopharmaceutical company’s stock valued at $747,000 after acquiring an additional 8,616 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Amarin by 54.2% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 39,455 shares of the biopharmaceutical company’s stock valued at $765,000 after acquiring an additional 13,862 shares during the period. Finally, Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Amarin by 3.6% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 22,357 shares of the biopharmaceutical company’s stock valued at $434,000 after acquiring an additional 775 shares during the period. Institutional investors own 44.94% of the company’s stock.

About Amarin

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.

Featured Story: Put Option

Analyst Recommendations for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.